DNMT3A and FLT3-ITD mutations have been found to be associated with adverse prognosis in patients with AML; however, few studies focused on the prognostic impact of these mutations in AML patients treated with allogeneic HSCT. Here, DNMT3A is linked to acute myeloid leukemia.